Incidence of COVID-19 Among Returning Travelers in Quarantine Facilities: A Longitudinal Study and Lessons Learned
Overview
Authors
Affiliations
Introduction: The emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) had resulted in an unpresented global pandemic. In the initial events, the Kingdom of Saudi Arabia implemented mandatory quarantine of returning travelers in order to contain COVID-19 cases.
Materials And Methods: This is a longitudinal study of the arriving travelers to Quarantine facilities and the prevalence of positive SARS-CoV-2 as detected by RT-PCR.
Results: During the study period, there was a total of 1928 returning travelers with 1273 (66%) males. The age range was 28 days-69 years. Of all the travelers, 23 (1.2%) tested positive for SARS-CoV-2. Of the first swab, 14/1928 (0.7%) tested positive. The positivity rate was 0.63% and 0.92% among males and females, respectively (P = 0.57). The second swab was positive in 9 (0.5%) of the other 1914 who were initially negative with a positivity rate of 0.39% and 0.62% among males and females, respectively (P = 0.49). There was no statistical difference in the positivity rates between first and second swab (P = 0.4). Of all travelers, 40 (n = 26, 1.3%) were admitted from the quarantine facility to the hospital due to COVID-19 related positive results or development of symptoms such as fever, cough, and respiratory symptoms; and 14 (0.7%) were admitted due to non-COVID-19 related illness.
Conclusion: This study showed the efforts put for facility quarantine and that such activity yielded a lower incidence of positive cases. There was a need to have a backup healthcare facility to accommodate those developing a medical need for evaluation and admission for non-COVID-19 related illnesses.
Lovey T, Hasler R, Gautret P, Schlagenhauf P J Travel Med. 2023; 30(5).
PMID: 37310895 PMC: 10481419. DOI: 10.1093/jtm/taad081.
Al-Tawfiq J, Kheir H, Al-Qahtani S, Jarrah M, Shalabi M, Hattab O IJID Reg. 2023; 6:142-145.
PMID: 36818018 PMC: 9916128. DOI: 10.1016/j.ijregi.2023.02.002.
Husser A, Ohnmacht T Tour Manag. 2023; 97:104734.
PMID: 36712143 PMC: 9874056. DOI: 10.1016/j.tourman.2023.104734.
Wu S, Wu X Front Public Health. 2022; 10:990400.
PMID: 36311571 PMC: 9609417. DOI: 10.3389/fpubh.2022.990400.
Mushcab H, Al-Tawfiq J, Ghamdi M, Babgi A, Amir A, Sheikh S Infect Drug Resist. 2022; 15:4393-4406.
PMID: 35974896 PMC: 9375977. DOI: 10.2147/IDR.S369755.